Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not ...

Novel agents were associated with improved overall survival (OS) and time to next treatment (TTNT) compared with historical therapies in adults 80 years and older treated for chronic lymphocytic ...